Castle Biosciences Inc reports results for the quarter ended in September - Earnings Summary

Castle Biosciences

02/11/2023 22:20

* Castle Biosciences Inc  CSTL.OQ  reported a quarterly
adjusted
loss of 26 cents​​ per share for the quarter ended in September,
higher than the same quarter last year, when the company
reported EPS of -77 cents.  The mean expectation of
eight analysts for the quarter was for a loss of 76 cents per
share. Wall Street expected results to range from $-1.03 to -47
cents per share.
    * Revenue rose 66.1% to $61.49 million from a year ago;
analysts
expected $48.52 million. 
    * Castle Biosciences Inc's reported EPS for the quarter was
a loss
of 26 cents​.
    * The company reported a quarterly loss of $6.91 million.
    * Castle Biosciences Inc shares had fallen by 7.0% this
quarter and lost 33.3% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 8 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the medical
equipment,
supplies & distribution peer group is also "strong buy"

Wall Street's median 12-month price target for Castle
Biosciences Inc is $32.50 
This summary was machine generated from LSEG data November 2 at
10:19 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      -0.76          -0.26          Beat
 Jun. 30 2023      -0.91          -0.70          Beat
 Mar. 31 2023      -0.89          -1.10          Missed
 Dec. 31 2022      -0.84          -0.78          Beat